User menu

Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians

Bibliographic reference Caers, Jo ; Vekemans, Marie-Christiane ; Bries, Greet ; Beel, Karolien ; Delrieu, Vanessa ; et. al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. In: Annals of Medicine, Vol. 45, no.5-6, p. 413-422 (2013)
Permanent URL http://hdl.handle.net/2078.1/144289
  1. Dammacco F, Clin Exp Immunol, 3, 911 (1968)
  2. Kyle Robert A, Monoclonal gammopathy of undetermined significance, 10.1016/0002-9343(78)90522-3
  3. Kyle R A, Durie B G M, Rajkumar S V, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole D H, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen W M, Anderson K C, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson P G, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, 10.1038/leu.2010.60
  4. Kyle Robert A., Therneau Terry M., Rajkumar S. Vincent, Offord Janice R., Larson Dirk R., Plevak Matthew F., Melton L. Joseph, A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance, 10.1056/nejmoa01133202
  5. Dispenzieri Angela, Katzmann Jerry A, Kyle Robert A, Larson Dirk R, Melton L Joseph, Colby Colin L, Therneau Terry M, Clark Raynell, Kumar Shaji K, Bradwell Arthur, Fonseca Rafael, Jelinek DF, Rajkumar S Vincent, Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study, 10.1016/s0140-6736(10)60482-5
  6. Blade Joan, Lopez-Guillermo Armando, Rozman Ciril, Cervantes Francisco, Salgado Camino, Aguilar Josep-Lluis, Vives-Corrons Joan-Lluis, Montserrat Emili, Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance, 10.1111/j.1365-2141.1992.tb08245.x
  7. Baldini L, Blood, 87, 912 (1996)
  8. Pasqualetti P, Casale R, Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance, 10.1016/s0753-3322(97)87730-x
  9. Gregersen H, Haematologica, 86, 1172 (2001)
  10. Cesana C., Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, 10.1200/jco.20.6.1625
  11. Rosiñol Laura, Cibeira M. Teresa, Montoto Silvia, Rozman María, Esteve Jordi, Filella Xavier, Bladé Joan, Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size, 10.4065/82.4.428
  12. Perez-Persona E., Vidriales M.-B., Mateo G., Garcia-Sanz R., Mateos M.-V., de Coca A. G., Galende J., Martin-Nunez G., Alonso J. M., de las Heras N., Hernandez J. M., Martin A., Lopez-Berges C., Orfao A., San Miguel J. F., New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells, 10.1182/blood-2007-05-088443
  13. Ucci G, Cooperative Group for the Study and Treatment of Multiple Myeloma. J Intern Med, 234, 165 (1993)
  14. Berenson JR, Br J Haematol, 150, 28 (2010)
  15. Kyle Robert A., Therneau Terry M., Rajkumar S. Vincent, Larson Dirk R., Plevak Matthew F., Offord Janice R., Dispenzieri Angela, Katzmann Jerry A., Melton L. Joseph, Prevalence of Monoclonal Gammopathy of Undetermined Significance, 10.1056/nejmoa054494
  16. Wadhera Rishi K., Rajkumar S. Vincent, Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review, 10.4065/mcp.2010.0337
  17. Greenberg A J, Vachon C M, Rajkumar S V, Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites, 10.1038/leu.2011.368
  18. Landgren O., Kristinsson S. Y., Goldin L. R., Caporaso N. E., Blimark C., Mellqvist U.-H., Wahlin A., Bjorkholm M., Turesson I., Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden, 10.1182/blood-2008-12-191676
  19. Landgren O., Kyle R. A., Hoppin J. A., Beane Freeman L. E., Cerhan J. R., Katzmann J. A., Rajkumar S. V., Alavanja M. C., Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study, 10.1182/blood-2009-02-203471
  20. Landgren O., Rajkumar S. V., Pfeiffer R. M., Kyle R. A., Katzmann J. A., Dispenzieri A., Cai Q., Goldin L. R., Caporaso N. E., Fraumeni J. F., Blot W. J., Signorello L. B., Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women, 10.1182/blood-2010-01-262394
  21. Kyle Robert A., Therneau Terry M., Rajkumar S. Vincent, Larson Dirk R., Plevak Matthew F., Melton L. Joseph, Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years Later, 10.4065/79.7.859
  22. Kristinsson S. Y., Bjorkholm M., Andersson T. M-L, Eloranta S., Dickman P. W., Goldin L. R., Blimark C., Mellqvist U.-H., Wahlin A., Turesson I., Landgren O., Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study, 10.3324/haematol.2009.010066
  23. Kyle R. A., Kumar S., The significance of monoclonal gammopathy of undetermined significance, 10.3324/haematol.2009.013961
  24. Poel M. H. W., Coebergh J. W. W., Hillen H. F. P., Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in Southeastern Netherlands, 10.1111/j.1365-2141.1995.tb05256.x
  25. Landgren O., Kyle R. A., Pfeiffer R. M., Katzmann J. A., Caporaso N. E., Hayes R. B., Dispenzieri A., Kumar S., Clark R. J., Baris D., Hoover R., Rajkumar S. V., Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study, 10.1182/blood-2008-12-194241
  26. Weiss B. M., Abadie J., Verma P., Howard R. S., Kuehl W. M., A monoclonal gammopathy precedes multiple myeloma in most patients, 10.1182/blood-2008-12-195008
  27. Ogmundsdottir Helga M., Haraldsdottir Vilhelmina, M. Johannesson Gudmundur, Olafsdottir Gudridur, Bjarnadottir Kristin, Sigvaldason Helgi, Tulinius Hrafn, Monoclonal gammopathy in Iceland: a population-based registry and follow-up, 10.1046/j.1365-2141.2002.03589.x
  28. Decaux Olivier, Cuggia Marc, Ruelland Annie, Cazalets Claire, Cador Bérangère, Jego Patrick, Grosbois Bernard, Suivi évolutif des gammapathies monoclonales de signification indéterminée, 10.1016/s0755-4982(06)74771-6
  29. Rajkumar S. V., Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance, 10.1182/blood-2005-03-1038
  30. Ocqueteau MF, Am J Pathol, 152, 1655 (1998)
  31. Pepe Jessica, Petrucci Maria Teresa, Nofroni Italo, Fassino Valeria, Diacinti Daniele, Romagnoli Elisabetta, Minisola Salvatore, Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance, 10.1111/j.1365-2141.2006.06217.x
  32. Melton L Joseph, Rajkumar S Vincent, Khosla Sundeep, Achenbach Sara J, Oberg Ann L, Kyle Robert A, Fracture Risk in Monoclonal Gammopathy of Undetermined Significance, 10.1359/jbmr.0301212
  33. Kristinsson S. Y., Tang M., Pfeiffer R. M., Bjorkholm M., Blimark C., Mellqvist U.-H., Wahlin A., Turesson I., Landgren O., Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study, 10.1182/blood-2010-04-282848
  34. Bida John P., Kyle Robert A., Therneau Terry M., Melton L. Joseph, Plevak Matthew F., Larson Dirk R., Dispenzieri Angela, Katzmann Jerry A., Rajkumar S. Vincent, Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients, 10.4065/84.8.685
  35. Pepe Jessica, Petrucci Maria Teresa, Mascia Maria Lucia, Piemonte Sara, Fassino Valeria, Romagnoli Elisabetta, Minisola Salvatore, The Effects of Alendronate Treatment in Osteoporotic Patients Affected by Monoclonal Gammopathy of Undetermined Significance, 10.1007/s00223-008-9145-2
  36. Berenson J. R., Yellin O., Boccia R. V., Flam M., Wong S.-F., Batuman O., Moezi M. M., Woytowitz D., Duvivier H., Nassir Y., Swift R. A., Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss, 10.1158/1078-0432.ccr-08-0666
  37. Kristinsson S. Y., Pfeiffer R. M., Bjorkholm M., Goldin L. R., Schulman S., Blimark C., Mellqvist U.-H., Wahlin A., Turesson I., Landgren O., Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study, 10.1182/blood-2009-11-252072
  38. Kristinsson S. Y., Fears T. R., Gridley G., Turesson I., Mellqvist U.-H., Bjorkholm M., Landgren O., Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma, 10.1182/blood-2008-04-151076
  39. Gregersen Henrik, Nørgaard Mette, Severinsen Marianne T., Engebjerg Malene C., Jensen Paw, Sørensen Henrik T., Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism : Venous thromboembolism in MGUS, 10.1111/j.1600-0609.2010.01539.x
  40. Sallah S., Husain A., Wan J., Vos P., Nguyen N. P., The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance, 10.1093/annonc/mdh385
  41. Srkalovic Gordan, Cameron Marte G., Rybicki Lisa, Deitcher Steven R., Kattke-Marchant Kandice, Hussein Mohamad A., Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease, 10.1002/cncr.20405
  42. Muslimani AA, Clin Adv Hematol Oncol, 7, 827 (2009)
  43. Cohen Adam L., Sarid Rami, The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease, 10.1016/j.thromres.2009.01.004
  44. Lamboley V, Seven new cases with a literature review. Joint Bone Spine, 69, 62 (2002)
  45. Federici AB, Blood, 92, 2707 (1998)
  46. Sanchorawala V., Light-Chain (AL) Amyloidosis: Diagnosis and Treatment, 10.2215/cjn.02740806
  47. Nobile-Orazio Eduardo, IgM paraproteinaemic neuropathies : , 10.1097/00019052-200410000-00010
  48. , European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Socie, 10.1111/j.1529-8027.2010.00278.x
  49. Gorson K. C, Ropper A. H, Axonal neuropathy associated with monoclonal gammopathy of undetermined significance, 10.1136/jnnp.63.2.163
  50. Nobile-Orazio E., Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies, 10.1093/brain/123.4.710
  51. Oksenhendler E, Chevret S, Leger J M, Louboutin J P, Bussel A, Brouet J C, Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group., 10.1136/jnnp.59.3.243
  52. Léger JM, Neurology (2013)
  53. Dalakas Marinos C., Rakocevic Goran, Salajegheh Mohammad, Dambrosia James M., Hahn Angelika F., Raju Raghavan, McElroy Beverly, Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy, 10.1002/ana.21577
  54. Kristinsson S. Y., Tang M., Pfeiffer R. M., Bjorkholm M., Goldin L. R., Blimark C., Mellqvist U.-H., Wahlin A., Turesson I., Landgren O., Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study, 10.3324/haematol.2011.054015
  55. Paueksakon Paisit, Revelo Monica P, Horn Robert G, Shappell Scott, Fogo Agnes B, Monoclonal gammopathy: significance and possible causality in renal disease, 10.1016/s0272-6386(03)00412-8
  56. Daoud Mazen S., Lust John A., Kyle Robert A., Pittelkow Mark R., Monoclonal gammopathies and associated skin disorders, 10.1016/s0190-9622(99)70434-2
  57. Bianchi G., Kyle R. A., Colby C. L., Larson D. R., Kumar S., Katzmann J. A., Dispenzieri A., Therneau T. M., Cerhan J. R., Melton L. J., Rajkumar S. V., Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications, 10.1182/blood-2010-04-277566
  58. Rajkumar S. Vincent, Kyle Robert A., Buadi Francis K., Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence, 10.4065/mcp.2010.0520